NextCure, Inc. (NXTC): Price and Financial Metrics
GET POWR RATINGS... FREE!
NXTC Stock Price Chart Interactive Chart >
NXTC Price/Volume Stats
| Current price | $1.63 | 52-week high | $5.68 |
| Prev. close | $1.67 | 52-week low | $1.16 |
| Day low | $1.59 | Volume | 53,000 |
| Day high | $1.65 | Avg. volume | 129,252 |
| 50-day MA | $1.48 | Dividend yield | N/A |
| 200-day MA | $3.23 | Market Cap | 45.27M |
NextCure, Inc. (NXTC) Company Bio
NextCure, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.
Latest NXTC News From Around the Web
Below are the latest news stories about NEXTCURE INC that investors may wish to consider to help them evaluate NXTC as an investment opportunity.
Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
NextCure to Present at Upcoming Investor ConferencesBELTSVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the following investor conferences: Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022, at 3:30 pm (ET) in New York City JMP Securities Hematology and Oncology Summit (Virtual) on |
NextCure, LegoChem Biosciences Ink Collaborative Pact For Antibody Drug ConjugatesNextCure Inc (NASDAQ: NXTC) and LegoChem Biosciences Inc announced a collaboration and co-development agreement to generate a B7-H4 antibody-drug conjugate (ADC) and options for two additional targets. The B7-H4 ADC will utilize NextCure's B7-H4 antibody and LCB's ConjuAllTM ADC technology. Under the terms of the agreement, both parties will equally share the costs to develop the molecules and profits on commercialized products. Related: NextCure Launches Early-Stage Study For NC762 In Solid Tum |
NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug ConjugatesBELTSVILLE, Md. and DAEJEON, South Korea, Nov. 15, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC) and LegoChem Biosciences, Inc. (LCB, KOSDAQ: 141080) today announced a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC) and options for two additional targets. The B7-H4 ADC will utilize NextCure’s B7-H4 antibody and LCB’s ConjuAllTM ADC technology. Under the terms of the agreement, both parties will equally share the costs to develop the |
NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual MeetingBELTSVILLE, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial investigator Emese Zsiros, M.D., Ph.D., Associate Professor of Oncology, Chair, Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, will present initial clinical data from a Phase 1 cl |
NXTC Price Returns
| 1-mo | 9.40% |
| 3-mo | -17.68% |
| 6-mo | -65.39% |
| 1-year | -69.53% |
| 3-year | -96.26% |
| 5-year | N/A |
| YTD | 15.60% |
| 2022 | -76.50% |
| 2021 | -44.95% |
| 2020 | -80.65% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...